
COUR Pharma
Founded: 2013
Northwestern Inventor:
Stephen Miller
Feinberg School of Medicine
Department of Microbiology-Immunology
Lonnie Shea
McCormick School of Engineering (formerly)
Department of Biomedical Engineering
COUR Pharma is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using its proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, the company develops first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.
Twitter: @CourPharma
LinkedIn: COUR Pharma